{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:28:57Z","timestamp":1771331337684,"version":"3.50.1"},"reference-count":49,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd016054","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:47:44Z","timestamp":1771328864000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["KRAS G12C inhibitors versus chemotherapy in second line and beyond in adults with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring the KRAS G12C mutation"],"prefix":"10.1002","volume":"2026","author":[{"given":"Anneloes","family":"Noordhof","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases; Frisius MC; Leeuwarden Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oke Dimas","family":"Asmara","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases; Radboud UMC; Nijmegen Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"de Jong","sequence":"additional","affiliation":[{"name":"Department of Epidemiology; Frisius MC; Leeuwarden Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolof GP","family":"Gijtenbeek","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases; Frisius MC; Leeuwarden Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ymkje MA","family":"Huitema","sequence":"additional","affiliation":[{"name":"Frisius MC Academy, Knowledge and Information Center; Frisius MC; Leeuwarden Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Femke HM","family":"van Vollenhoven","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases; Frisius MC; Leeuwarden Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben JW","family":"Venmans","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases; Frisius MC; Leeuwarden Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizza","family":"Hendriks","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, GROW - Research Institute for Oncology and Reproduction; Maastricht University Medical Center; Maastricht Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5976-0974","authenticated-orcid":false,"given":"Wouter H","family":"van Geffen","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases; Radboud UMC; Nijmegen Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD016054-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"3","key":"10.1002\/14651858.CD016054-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"9","key":"10.1002\/14651858.CD016054-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.jtho.2023.06.010","article-title":"Lung cancer in Indonesia","volume":"18","author":"Asmara","year":"2023","journal-title":"Journal of Thoracic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD016054-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5334\/aogh.2419","article-title":"Global epidemiology of lung cancer","volume":"85","author":"Barta","year":"2019","journal-title":"Annals of Global Health"},{"issue":"3","key":"10.1002\/14651858.CD016054-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jtho.2020.10.012","article-title":"Lung cancer in the Netherlands","volume":"16","author":"Hendriks","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"issue":"12","key":"10.1002\/14651858.CD016054-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","article-title":"Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US","volume":"7","author":"Ganti","year":"2021","journal-title":"JAMA Oncology"},{"issue":"9","key":"10.1002\/14651858.CD016054-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","article-title":"The global burden of lung cancer: current status and future trends","volume":"20","author":"Leiter","year":"2023","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD016054-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Annals of Oncology"},{"issue":"8","key":"10.1002\/14651858.CD016054-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1002\/14651858.CD016054-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.lungcan.2021.04.001","article-title":"Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy","volume":"155","author":"Noordhof","year":"2021","journal-title":"Lung Cancer"},{"issue":"July","key":"10.1002\/14651858.CD016054-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"107293","DOI":"10.1016\/j.lungcan.2023.107293","article-title":"KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing","volume":"184","author":"Lim","year":"2023","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1002\/14651858.CD016054-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.21037\/tlcr-20-455","article-title":"KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples","volume":"9","author":"Loong","year":"2020","journal-title":"Translational Lung Cancer Research"},{"issue":"7","key":"10.1002\/14651858.CD016054-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"7684","DOI":"10.18632\/oncotarget.23969","article-title":"Association between PD-L1 expression and driver gene status in nonsmall- cell lung cancer: a meta-analysis","volume":"9","author":"Lan","year":"2018","journal-title":"Oncotarget"},{"issue":"7","key":"10.1002\/14651858.CD016054-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1002\/cncr.31871","article-title":"Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1\/PD-L1 inhibitors in patients with oncogene-driven non\u2013small cell lung cancer","volume":"125","author":"Ng","year":"2019","journal-title":"Cancer"},{"issue":"9","key":"10.1002\/14651858.CD016054-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.annonc.2021.06.001","article-title":"Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches","volume":"32","author":"Reck","year":"2021","journal-title":"Annals of Oncology"},{"issue":"21","key":"10.1002\/14651858.CD016054-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers14215430","article-title":"KRAS in NSCLC: state of the art and future perspectives","volume":"14","author":"Cascetta","year":"2022","journal-title":"Cancers"},{"issue":"9","key":"10.1002\/14651858.CD016054-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"100543","DOI":"10.1016\/j.jtocrr.2023.100543","article-title":"Prognostic implication of KRAS G12C mutation in a real-world KRAS-mutated stage IV NSCLC cohort treated with immunotherapy in the Netherlands","volume":"4","author":"Noordhof","year":"2023","journal-title":"JTO Clinical and Research Reports"},{"issue":"14","key":"10.1002\/14651858.CD016054-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of ras mutations in cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Research"},{"issue":"17","key":"10.1002\/14651858.CD016054-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"10027","key":"10.1002\/14651858.CD016054-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD016054-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"19","key":"10.1002\/14651858.CD016054-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD016054-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD016054-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ebiom.2019.02.049","article-title":"KRAS-mutant non-small cell lung cancer: converging small molecules and immune checkpoint inhibition","volume":"41","author":"Adderley","year":"2019","journal-title":"EBioMedicine"},{"issue":"7781","key":"10.1002\/14651858.CD016054-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1002\/14651858.CD016054-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1021\/acs.jmedchem.9b01180","article-title":"Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors","volume":"63","author":"Lanman","year":"2020","journal-title":"Journal of Medicinal Chemistry"},{"issue":"7477","key":"10.1002\/14651858.CD016054-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nature12796","article-title":"KRAS (G12C) inhibitors alloserically control GTP affinity and effector interactions. Supplementary information","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"issue":"25","key":"10.1002\/14651858.CD016054-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/nejmoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.g12c mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD016054-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"10378","key":"10.1002\/14651858.CD016054-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open- label, phase 3 trial","volume":"401","author":"De Langen","year":"2023","journal-title":"Lancet"},{"issue":"17","key":"10.1002\/14651858.CD016054-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"LBA8509","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8509","article-title":"KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced\/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation","volume":"42","author":"Mok","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"10503","key":"10.1002\/14651858.CD016054-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(25)00866-9","article-title":"Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial","volume":"406","author":"Barlesi","year":"2025","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD016054-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.chest.2024.05.026","article-title":"The proposed ninth edition TNM classification of lung cancer","volume":"166","author":"Detterbeck","year":"2024","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD016054-BIB0034|cit34","first-page":"67","article-title":"Patient-reported outcomes in cancer clinical trials: cancer institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"35","author":"Kluetz","year":"2016","journal-title":"Asco Educational Book 73"},{"key":"10.1002\/14651858.CD016054-BIB0035|cit35","unstructured":"European Organisation For Research and Treatment of Cancer https:\/\/qol.eortc.org"},{"key":"10.1002\/14651858.CD016054-BIB0036|cit36","unstructured":"Core Outcome Measures in Effectiveness Trials https:\/\/www.comet-initiative.org"},{"key":"10.1002\/14651858.CD016054-BIB0037|cit37","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016054-BIB0038|cit38","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Chapter 4: Searching for and selecting studies (chapter last updated March 2025). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5.1 (updated 2025). Cochrane, 2025 Available from https:\/\/cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD016054-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan - a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD016054-BIB0040|cit40","unstructured":"Review Manager (RevMan) The Cochrane Collaboration"},{"key":"10.1002\/14651858.CD016054-BIB0041|cit41","unstructured":"Boutron I Page MJ Higgins JP Altman DG Lundh A Hr\u00f3bjartsson A Chapter 7: Considering bias and conflicts of interest among the included studies (chapter last updated August 2022). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016054-BIB0042|cit42","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016054-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016054-BIB0044|cit44","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect (chapter last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016054-BIB0045|cit45","unstructured":"Deeks JJ Higgins JP Altman DG McKenzie JE Veroniki AA Chapter 10: Analysing data and undertaking meta-analyses (chapter last updated November 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016054-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"4861","DOI":"10.1002\/sim.6301","article-title":"The Peto odds ratio viewed as a new effect measure","volume":"33","author":"Brockhaus","year":"2014","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD016054-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD016054-BIB0048|cit48","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence (chapter last updated August 20230. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016054-BIB0049|cit49","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2024"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:47:47Z","timestamp":1771328867000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD016054"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd016054","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]}}}